Asthma treatment

51. (USA) – December 28, 2007 GlaxoSmithKline Tests Show Advair Edge Over Pfizer’s Spiriva In Treating COPD December 28, 2007 ( ) GlaxoSmithKline Plc (NYSE: GSK) said that clinical trial results showed its top-seller Advair had an edge over Pfizer Inc. ’s (NYSE: PFE) rival product Spiriva in treating patients with the lung disease COPD. Glaxo said that a two-year study of 1, 300 patients found both drugs had a similar impact on rate of exacerbations, but people treated with Advair gained a significant improvement in health status and greater survival benefit than ….. (USA) – July 21, 2006 Biopsy Study Shows Combination of Long-Acting Beta2-Agonist and Low Steroid Dose in Advair Diskus(R) 100/50mcg Maintains Control of Airway Inflammation, Study Supports National Institute of Health Guidelines for the Diagnosis and Management of Asthma The largest biopsy study conducted to date demonstrates that a lower dose of an inhaled corticosteroid (ICS) with the addition of a long acting beta2-agonist (LABA) is as effective in maintaining control of airway inflammation as a medium-dose ICS alone in patients with moderate asthma. The study, published in the July issue of the Journal of Allergy and Clinical Immunology (JACI), compared Advair Diskus (fluticasone propionate and salmeterol) 100/50 mcg with fluticasone ….. wire (USA) – December 1, 2008 Advair’s Patient Share in Newly Diagnosed Asthma Patients is Declining, Surveyed Physicians Will Continue to Use Singulair Regardless of March 2008 Suicidality Claim, According to a New Report from Decision Resources PRNewswire — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline’s Advair is declining in all lines of therapy for newly diagnosed asthma patients. The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12. 2 percent, 13. 6 percent, and 14. 6 percent, respectively when ….. Datamonitor – August 9, 2007 FDA rejects higher dose of GSK’s Advair GlaxoSmithKline has said that the FDA has declined to approve its supplemental drug application for the 500/50 strength of Advair Diskus in the treatment of patients with chronic obstructive pulmonary disease. The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing recommendations. GSK says it will be meeting with the FDA to discuss this request in more detail and determine next steps, including discussion of ….. , The (NC) – March 7, 2006 ADVAIR AND SEREVENT TO GET NEW WARNINGS The asthma medication Advair and a related drug Serevent will bear stronger warnings of an increased risk of death associated with one ingredient. Advair is GlaxoSmithKline’s best-selling product, and Serevent is another of the British company’s drugs. The updated warnings on both drugs caution that salmeterol may increase the risk of asthma-related death. Advair should be used only by patients when other asthma drugs, such as low- to medium-dose inhaled ….. (PA) – December 11, 2008 FDA panel: Keep Advair on the market Dec. 11–An FDA committee unanimously recommended today that GlaxoSmithKline PLC’s drug Advair should remain on the market to treat asthma in adults. The full FDA will use the advisory committee’s vote later to make a decision on the drug. The committee also said Advair should remain on the market for patients age 12 to 17. But the FDA advisory committee also said GlaxoSmith’s drug Serevent should no longer be used to treat asthma in children or ….. (KY) – December 6, 2008 Risks of new asthma drugs vary, FDA studies find, fewer complications seen with advair WASHINGTON – The blockbuster asthma drug Advair does not appear to have an increased risk of serious respiratory complications seen with similar new medicines, federal health officials said Friday. But a less widely used medication, Serevent, had a significantly higher rate of complications when compared to older treatments, the Food and Drug Administration said. Both drugs are made by the same company, GlaxoSmithKline. FDA safety reviewers are recommending that Serevent no longer be …. Datamonitor – March 29, 2006 Positive trial for GSK’s Advair in lung disease GlaxoSmithKline has announced positive preliminary results from a survival study evaluating its asthma drug Advair in patients with chronic obstructive pulmonary disease. Results from the 6, 100-patient trial show a 17% relative reduction in mortality over three years for patients receiving 50/500 micrograms of Advair as compared with patients on placebo. This is the first study to investigate the effects of pharmacotherapy on all-cause mortality in patients with chronic ….. Daily Mail, The (London, England) – November 22, 2005 Daily Mail: GSK faces tough new restrictions on Advair DRUG firm GlaxoSmithKline has been dealt a major blow by US regulators who have imposed tough new restrictions on the use of Advair, its biggest product. The Food & Drug Administration says the asthma treatment should be prescribed only when other medicines have failed, and not as a frontline remedy. The FDA acted after a clinical study showed drugs such as Advair – which use an ingredient called ‘ longacting beta agonists’ – can sometimes trigger ….. Knight-Ridder/Tribune Business News – May 1, 2003 Asthma Drug Advair Breathes Life into GlaxoSmithKline’s Bottom-Line Profit May 1 RESEARCH TRIANGLE PARK, N. C. Surging sales of GlaxoSmithKline’s powerhouse asthma drug Advair more than compensated for the big hit its antibiotic Augmentin suffered from generic competition, enabling the word’s second-largest drug company to post a 17 percent gain in profits. The bottom-line profit of $1. 91 billion, compared with $1. 64 billion a year ago, exceeded the average estimate of analysts surveyed by Bloomberg News. Revenue growth ….